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Abstract: TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use which carries the
triazene group as cytotoxic principle. The purpose of the study was to determine the maximum toler-
ated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755 in
tumor bearing dogs. Additionally, tumor response was monitored and assessed after chemotherapy as a
secondary goal. Treatment schedule consisted of IV administration of the drug over 20 minutes on two
consecutive weeks per month for a total of three cycles. Thirty tumor bearing dogs were included in the
study. The starting dose was 25 mg/kg and the escalation steps occurred in increments of 20% of the
previous dose. The MTD was 74.6 mg/kg. The DLT was characterized by gastrointestinal adverse events
only. The pharmacokinetic of TriN 2755 and its main metabolites in plasma and sputum are described
in a two compartment model. The response rate for 19/30 dogs was 47.3% (6 partial remission, 3 stable
disease) and the median progression-free interval (PFI) for the responders was 47d (range 21-450d). In
summary, this study demonstrated a safe and tolerable dose of TriN 2755 for IV use in tumor bearing
dogs. The adverse events were mild in severity and limited only in fatigue and gastrointestinal upset. =
TriN 2755 ist eine alkylierende, antineoplastische Substanz für intravenöse (IV) Verabreichung, das die
Triazenegrouppe als zytotoxisches Prinzip trägt. Ziel dieser Studie war die Bestimmung der maximalen
tolerierbaren Dosis (MTD), der Dosis-limitierenden Toxizität (DLT) und des pharmakokinetischen Pro-
fils von TriN 2755 in Hunden mit Tumoren. Die Ansprache auf die Chemotherapie wurde zusätzlich als
sekundäres Ziel kontrolliert und bewertet. Der Behandlungsplan bestand aus der IV Verabreichung von
TriN 2755 über 20 Minuten an zwei aufeinanderfolgenden Wochen pro Monat für drei Zyklen. Dreissig
Hunden mit Tumoren wurden in die Studie eingeschlossen. Die Anfangsdosis war 25 mg/kg und die
Eskalationsstufen erfolgten in 20%-Schritten der vorherigen Dosis. Die MTD war 74,6 mg/kg. Als dosis-
limitierende Toxizität wurden nur gastrointestinale Nebenwirkungen beobachtet. Die Pharmakokinetik
von TriN 2755 und seinen Hauptmetaboliten im Plasma und Sputum sind in einem zwei Kompartiment-
Modell beschrieben. Die Ansprache-Rate für 19/30 Hunde erreichte 47,3% (6 partielle Remission und 3
stabile Erkrankung) und die mediane progressionsfreie Intervall für die Hunde, die angesprochen haben,
war 47 Tage (21-450 Tage). Zusammenfassend konnte in dieser Studie gezeigt werden, dass es neben-
wirkungsarme, tolerierbare Dosis von TriN 2755 für IV Verabreichung bei Hunden mit Tumoren gibt.
Die Nebenwirkungen waren mild und selbstlimitierend, aus Müdigkeit und gastrointestinale Störungen
bestehend.
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NOVEL TRIAZENE TriN 2755 IN TUMOR BEARING DOGS 
TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use which carries 
the triazene group as cytotoxic principle. The purpose of the study was to determine the 
maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic 
(PK) profile of TriN 2755 in tumor bearing dogs. Additionally, tumor response was 
monitored and assessed after chemotherapy as a secondary goal. Treatment schedule 
consisted of IV administration of the drug over 20 minutes on two consecutive weeks per 
month for a total of three cycles. Thirty tumor bearing dogs were included in the study. 
The starting dose was 25 mg/kg and the escalation steps occurred in increments of 20% 
of the previous dose. The MTD was 74.6 mg/kg. The DLT was characterized by 
gastrointestinal adverse events only. The pharmacokinetic of TriN 2755 and its main 
metabolites in plasma and sputum are described in a two compartment model.  The 
response rate for 19/30 dogs was 47.3% (6 partial remission, 3 stable disease) and the 
median progression-free interval (PFI) for the responders was 47d (range 21-450d). In 
summary, this study demonstrated a safe and tolerable dose of TriN 2755 for IV use in 
tumor bearing dogs. The adverse events were mild in severity and limited only in fatigue 
and gastrointestinal upset. 
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Verabreichung, das die Triazenegrouppe als zytotoxisches Prinzip trägt. Ziel dieser 
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limitierenden Toxizität (DLT) und des pharmakokinetischen Profils von TriN 2755 in 
Hunden mit Tumoren. Die Ansprache auf die Chemotherapie wurde zusätzlich als 
sekundäres Ziel kontrolliert und bewertet. Der Behandlungsplan bestand aus der IV 
Verabreichung von TriN 2755 über 20 Minuten an zwei aufeinanderfolgenden Wochen 
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eingeschlossen. Die Anfangsdosis war 25 mg/kg und die Eskalationsstufen erfolgten in 
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Hunden mit Tumoren gibt. Die Nebenwirkungen waren mild und selbstlimitierend, aus 
Müdigkeit und gastrointestinale Störungen bestehend. 
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 Abbreviated title: TriN 2755 for canine malignant tumors 
 
Abstract: TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use which carries the 
triazene group as cytotoxic principle. The purpose of the study was to determine the maximum 
tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 
2755 in tumor bearing dogs. Additionally, tumor response was monitored and assessed after 
chemotherapy as a secondary goal. The starting dose was 25 mg/kg and the MTD was 74.6 mg/kg. 
The DLT was characterized by gastrointestinal adverse events only. The pharmacokinetic of TriN 
2755 and its main metabolites in plasma and sputum are described in a two compartment model.  The 
response rate for 19/30 dogs was 47.3% (6 partial remission, 3 stable disease) and the median 
progression-free interval (PFI) for the responders was 47d (range 21-450d). 
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Introduction:                                                                                                                                                       
Triazenes are established alkylating chemotherapeutic compounds in clinical use in humans and dogs, 
which can induce apoptosis in susceptible tumors and act as antimetastatic agents.1, 2  The triazenes 
drugs that are of main clinical interest include dacarbazine (DTIC) and temozolomide (TMZ). These 
two compounds have similar chemical, physical, antitumor and mutagenic properties.1                                                                                                                                                                       
TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use with a unique chemical 
structure, which carries the triazene group as a cytotoxic principle. Although TriN 2755 belongs to the 
group of triazene compounds, it differs due to its physicochemical properties as well as its potent 
antineoplastic activity. TriN 2755 is highly photostable and hydrophylic, showing potent dose 
dependent antitumor activity in a variety of human cancer xenografts in murine models including also 
DTIC resistant tumors.3 Pharmacokinetic studies in rats and healthy beagle dogs demonstrated a dose 
dependent increase of the plasma concentration and area under the curve (AUC) of TriN 2755, 
following intravenously administration of the drug. TriN 2755 is well tolerated in these species 
(Investigator´s Brochure, Trin Therapeutics GmbH, Düsseldorf, Germany).                                                                                                                                                                                                                                                                                                                               
A phase I clinical trial with the use of TriN 2755 was initiated in tumor bearing dogs, where no 
treatment existed or showing resistance to standard chemotherapy treatment. The purpose of the study 
was to determine the maximally tolerated dose (MTD) of TriN 2755, to look at the adverse events 
(AE) profile and, to correlate toxicity to pharmacokinetic profile. Additionally, tumor response was 
monitored and assessed as a secondary goal.  
 
Material and Methods: 
Patient Eligibility Criteria: Dogs presented to the Vetsuisse Faculty, University of Zurich, 
Switzerland with histologically or cytologically confirmed neoplastic disease were prospectively 
enrolled in this study if they were refractory to standard of care treatment, if the owner declined other 
treatment, or if no established standard of care existed. In order to meet inclusion criteria, dogs 
required adequate hematological, renal, and hepatic function and absence of any serious systemic 
disorder incompatible with the study. However some patients were included in the study regardless 
moderate hematological and chemistry changes and/or moderate clinical condition, if the owner 
desired a `last chance´.  Prior chemotherapy treatment had to be terminated at least three weeks before 
entering the study. Written owner´s consent was obtained and the study was approved by the Animal 
Ethics Council of the Canton of Zurich, Switzerland.  
Study Design and Drug Administration: This trial was a phase I dose-escalating, open-label 
assessment of safety and toxicity of TriN 2755 in client-owned dogs with spontaneously occurring 
tumors. The assessment and treatment was initially carried out on three dogs, in dose-escalating 
cohorts using a traditional 3+3 design.4, 5 Escalation was performed according to Vail5 where the dose 
was escalated if none of three dogs of one dose cohort developed dose-limiting toxicity (DLT). If one 
of the three dogs of a cohort experienced DLT, at least three more dogs were included at the same 
dose level. Dose escalation was stopped, if two or more dogs of a cohort of three, or an extended 
cohort of six patients, respectively, developed DLT; the dose of this cohort was the maximally 
administered dose. The maximally tolerated dose (MTD) was defined as the dose of the highest dose 
level in which no more than one of six dogs develops DLT.5 The escalation steps occurred in 
increments of 20% of the previous dose. Starting dose was 25 mg/kg, based on 50% of the MTD 
according to experimental beagle data (Investigator´s Brochure, Trin Therapeutics GmbH, Düsseldorf, 
Germany).5                                                                                                                                                                   
The treatment schedule consisted of IV administration of the drug over 20 minutes on two consecutive 
weeks per month for a total of three cycles. In turn, dogs were evaluated every week for adverse 
events and tumor response. If no progression was noted at the end of the three cycles, treatment with 
TriN 2755 was continued at the same dose level but on an every two weeks schedule.                                                                                                                                                                   
TriN 2755 (Trin Therapeutics GmbH, Düsseldorf, Germany) for in vivo administration was provided 
as a powder; the powder was diluted with sterile water for injection, to obtain a concentration of 
2mg/ml. The calculated dose was given as an IV infusion in parallel with 250 ml 0.9% saline over a 
20-minute interval through the PhaSeal system. Supportive care (e.g. antiemetics and or antidiarrheal 
drugs) was administered after occurrence of AE and was provided prophylactically after the next 
administration of drug. Maropitan (2 mg/kg, SID, orally or subcutaneously) or Ondasentron (0.1-0.2 
mg/kg, BID, orally or IV) was given against nausea and emesis, and Metronidazol (15mg/kg, BID, 
orally or IV) against diarrhea. Medication allowed for disease unrelated comorbidity and/or further 
supportive care included steroids and non-steroidal anti-inflammatory drugs (NSAIDs). Antibiotics 
were prescribed in case of additional infection related or unrelated to the tumor (e.g. urinary tract 
infection, infection of tumor). Analgesics such as tramadol or NSAID for tumor-associated pain were 
allowed.                                                                                                                                                            
Toxicity Assessment: Dogs were evaluated for toxicity weekly before each treatment, and one week 
after the last chemotherapy; evaluation of toxicity to determine the MTD was done after the first dose 
only. The AE were monitored by performing a physical examination, complete blood count (CBC) and 
serum biochemistry at each scheduled appointment. Owners were asked to keep a diary on animal’s 
performance at home. Blood results and signs of AE were graded according to the VCOG-CTCAE 
v1.1.6 Toxicity criteria considered as unacceptable which lead to discontinuation of the trial were 
defined as ≥ grade 3 toxicity, except hematological toxicities, where ≥ grade 4 considered 
unacceptable. The trial also included heavily pretreated patients with an advanced stage of disease, 
thus a baseline status of symptoms using the same criteria was recorded for each dog before the trial 
started.                                                                                                                                             
Tumor Response Assessment: Due to the dose-escalating nature of this trial, response to treatment 
was only a secondary goal. Tumor size (locoregional and systemic) was assessed at study entry, before 
each drug administration if the tumor was measurable without the confirmation of diagnostic imaging 
(e.g. peripheral lymphnodes, skin tumors), and three weeks after the last treatment by means of caliper 
measurements and additional diagnostic imaging according to the tumor. For intra-thoracic and intra-
abdominal tumors re-evaluation (thoracic radiographs and eventually abdominal ultrasound) was also 
performed in the 5th or 6th week after the first administration of TriN 2755. Response was assessed as 
follows: in dogs with disseminated histiocytic sarcoma (DHS) and other solid tumors, response was 
measured according to the revised RECIST guideline v1.1. 7 The sum of diameters of all target lesions 
was calculated and reported as the baseline sum diameter. In dogs with multicentric lymphoma, 
criteria according to the VCOG consensus document for peripheral nodal lymphoma were used.8 
Lymph nodes were measured using calipers and the mean sum of the longest diameter of a maximum 
of five target lesions was calculated. According to both guidelines, responses were considered to be 
complete if all target lesions had disappeared (or lymph nodes were of normal size, respectively), 
partial (PR) if a 30% decrease of the sum of target lesion diameters occurred, or progressive (PD) if 
new lesions occurred or if there was an increase of at least 20% in the sum of target lesion diameters, 
taking as reference the smallest sum of the study. Dogs that showed neither sufficient shrinkage, to 
qualify for PR, nor sufficient increase to qualify for PD were considered to have stable disease (SD).7, 8  
Pharmacokinetic Evaluation: Blood samples were evaluated at least in one dog of every dose-group 
before, at the end and 0.5, 1, 2, 3, and 4 hours after IV TriN 2755 infusion. Blood was collected in 
tubes containing EDTA. Samples were put immediately on ice and centrifuged for 10 minutes at 4°C 
by 2000 x g. Supernatant plasma was removed and stored at -80°C until further analysis. In addition, 
samples from emesis (four in total) were collected and stored at -80°C until further analysis.  Plasma 
and emesis samples were analyzed by a validated LC-MS-HPLC method; in brief, a rapid and 
sensitive liquid chromatography-mass spectrometry (LC–MS) method combined with ultraviolet (UV) 
detection was developed and validated for the quantitative determination of TriN2755 and its 
metabolites from aliquots of ethylenediaminetetra-acetic acid (EDTA) plasma. The sample extraction 
and cleaning-up involved a simple solid phase extraction. Chromatographic separations were achieved 
on a reversed phase C18 column eluted at a flow-rate of 1.00 ml/min on a gradient of formic acid, 
methanol and acetonitrile. The overall cycle time of the method was 40 minutes. The monitored 
masses using electrospray ionisation were 193, 198, 214, 215 and 256 (m/z) for TriN2755 and its 
putative metabolites, respectively. For UV detection, a wavelength of 300 nm was used. The 
calibration curves were linear over the range of 3.00–400 ng/ml with the lower limit of quantification 
(LLQ) validated at 3.00 ng/ml for MS detection and between 400 ng/ml up to 100 µg/ml using UV 
detection at 300 nm. The results obtained during the validation of this method fulfill all requirements 
and recommendations, generally accepted for bioanalytical studies.9-11 The within-run and between-
run precisions, also at the levels of LLQ and upper limit of quantification (ULQ), ranged between 3.0 
and 10.8% (as [%] coefficient of variation (cv)), while the accuracy (as [%]bias) ranged from +1.1 to -
8.6%. The within-run and between-run precisions in this range were within 4.99%, while the accuracy 
ranged from 95.8 to 100.3%. The method was successfully applied to samples derived from this 
clinical phase I study.  
Statistical analysis: Plasma pharmacokinetic parameters, area under the curve (AUC), maximum 
concentration (Cmax), time to maximum concentration (Tmax), and elimination half-life (t1/2) for 
TriN 2755 and its metabolites were calculated using a two-compartment disposition model (program 
TOPFIT 2.0).12 The linear-logarithmic trapezoidal method was used to calculate AUC, and apparent 
t1/2 was calculated by linear least squares regression after logarithmic transformation of the terminal 
concentrations.   
  
Results: 
Patient Characteristics: A total of 30 client-owned dogs were included in the study between April 
2011 and July 2013. Patient’s population consisted of dogs of various breeds; the most common breed 
was the Bernese Mountain Dog (BMD) (n=13). Other breeds included are shown in Table 1. Median 
age upon study entry was 8.3 years (range 4.3-14.6 years) and median weight 35.7 kg (range 8.7-60.1 
kg). Nine dogs were intact (3 females, 6 males), eleven were castrated males and ten spayed females. 
Different types of tumors were included; the most common primary tumor was histiocytic sarcoma 
(HS) (n=14). Thirteen dogs had the disseminated form (DHS) and one had the localized form (LHS). 
The most common anatomical location for the DHS was the lung (n=8), followed by spleen (n=3), 
tracheobronchial lymphnodes (n=2), liver (n=2), mediastinal and abdominal lymphnodes, eye, bone 
and, kidney. The dog with the LHS had the tumor in its right elbow region. Other tumors included are 
shown in Table 1. More than half of the dogs had not received any prior treatment (n=18), whereas 
twelve dogs of the study had either chemotherapy (6 with malignant lymphoma and 1 with 
disseminated HS), surgery (2 splenic hemangiosarcomas) or radiation therapy (the two malignant 
melanomas) before receiving TriN 2755. The dog with the localized LHS had radiation therapy and 
received TriN 2755 as additional chemotherapy.  All six dogs with malignant lymphoma showed 
multicentric involvement stage III-V, substage a or b disease and clinical resistance towards several 
previous chemotherapy protocols. 
Drug Administration: Patients were divided into eight different dose groups from 25 mg/kg to 89.5 
mg/kg with increments of 20%. The groups consisted of three dogs; one of the three dogs from the 
fifth group experienced DLT and three additional dogs were added to this group. None of the three 
additive dogs experienced any DLT, thus the dose escalation was continued. At the MTD level three 
confirmatory patients were added.  
33% (10/30) of the enrolled patients completed the three cycles as planned and two of these continued 
treatment due to partial remission or stable disease; 2 patients with DHS had 18 and 9 applications of 
TriN 2755, respectively. Nineteen dogs received TriN 2755 only 2-4 times because of tumor 
progression or because of owner´s wish to discontinue (e.g. dogs in end-stage disease at entry without 
signs of improvement). This applied to the patients that had 2 applications of TriN 2755. One dog of 
the study received TriN 2755 only once because it died 8 days after the first chemotherapy; the cause 
of death in this case was unrelated to the tumor or the chemotherapeutic agent.  8/30 dogs received 
concurrent NSAIDs and 11/30 received steroids (oral prednisolone). Of the six lymphoma patients 
only one received steroids during the treatment with TriN 2755. 
                                                                                                                 
Toxicity Assessment: The toxicity was assessed after the first administration of TriN 2755. Over the 
12-week period, overall side effects were mild and rarely dose-limiting, as summarized in Table 2.                                                                                                                                
Hematological and biochemical parameters: 
Hematological and biochemical changes were not observed in any of the patients receiving the study 
drug. 14/30 dogs had already hematological and biochemical abnormalities at the time of inclusion 
either due to concurrent disease or due to causes related to the tumor. 
Gastrointestinal effects: 
Main gastrointestinal AE were anorexia, diarrhea, nausea and vomiting beginning within 24 h after the 
end of the infusion of TriN 2755. 3/30 dogs of the study experienced dose-limiting toxicities due to 
diarrhea and vomiting. When occurrence of gastrointestinal AE was detected after the first drug 
administration, supportive care was administered in 24/30 dogs. Not all AE were considered to be 
related to TriN 2755 administration; in some dogs, observed toxicities were rather related to disease 
progression or to treatment-unrelated concurrent morbidities.  
Other effects: 
Grade 1-2 fatigue was observed in 19/30 dogs after the first administration of TriN 2755.  
Table 2 provides a summary of the adverse events noted after the first administration of the study drug 
approximately within 24h. 
Maximally Tolerated Dose: TriN 2755 was well tolerated up to a dose of 74.6 mg/kg. At the next 
higher dose level of 89.5 mg/kg, two of three dogs showed dose-limiting gastrointestinal toxicity grade 
3, therefore the cohort study stopped. MTD for TriN 2755 application was determined to be 74.6 
mg/kg.  
Tumor Response Assessment: Preliminary antitumor activity was examined only in patients that 
have completed the first cycle and received at least 3 times TriN 2755. In addition, one dog (patient 
29) with metastatic lung adenocarcinoma receiving 4 times TriN 2755 was excluded from the 
response-analysis due to difficulties in evaluating the tumor because of an almost continuous 
production of free fluid in the thorax; therefore, the response was evaluated in 19/30 dogs. At the end 
of all TriN 2755 treatments (range 3-18), 6 (33%) dogs showed PR, 3 (16%) dogs SD, and 10 (52%) 
PD.  
From the dogs with PR one was a BMD with DHS (18 administrations of TriN 2755, PFI 450 days), 
four dogs had multicentric lymphoma Stage IV-V, substage a-b (3-4 administrations of TriN 2755, PFI 
ranged 21-51 days) and one dog had subcutaneous malignant melanoma (3 administrations of TriN 
2755, PFI 74 days).  
All three dogs with SD disease completed the three cycles of TriN 2755 (treatments ranged from 6 to 
9); one BMD with DHS (splenic form, PFI 139 days), one dog with LHS (PFI 117 days) and one dog 
with gastric adenocarcinoma (PFI 126 days).  
6/10 dogs with PD were BMD with DSH; all dogs completed three cycles of TriN 2755 (median PFI 
78.5 days, range 63-91 days).    
Table 1 provides a summary of the patients and the response by cohort. 
Pharmacokinetic of Plasma: The pharmacokinetic of TriN 2755 and its main metabolites in this 
infusion protocol is well described with a two compartment disposition model. An example is given in 
Figure 1; one dog of cohort 8 was treated with 89.6mg/kg TriN 2755. TriN 2755 and its main 
metabolites M1, M3 and M4 were analyzed within 4 hours after start of the slow bolus injection. By 
using a two compartment model, extrapolation to infinity was possible. AUC as well as Cmax of the 
given drug TriN 2755 increased in a linear manner with dose (r² = 0.92 and 0.86, respectively). We 
obtained a higher deviation from linearity in AUC calculation for the main metabolites M1 and M4, 
and even a worse correlation for Cmax calculation. Tmax of TriN 2755 was obtained at the end of 
infusion (about 20 min), the calculated Tmax for M1 was 0.82 +/- 0.08 h (mean +/- SD), about 30 min 
after end of infusion. The calculated Tmax of metabolite M4 was 1.64 +/- 0.49 h, more than 75 min 
after end of infusion. Terminal half-lives were 0.60 +/- 0.18 h for TriN 2755, 0.82 +/- 0.09 h for M1, 
and 1.34 +/- 0.43 h for M4, respectively. PK calculations for metabolite M3 were not possible in all 
cases. Therefore, single values are not presented (Table 3). 
Analysis of sputum: 6 dogs of the study vomited orange/red fluid 2-6 hours after the administration 
of the study drug. All these dogs received TriN 2755 at a dose equal or more than 62.2 mg/kg.                                                                                                                                                                   
Four samples of sputum from 3 dogs were collected for further investigation.                                             
2/4 samples were from the same dog (patient 21); collected in the first 2 h and the second 5.5 h after 
the administration of TriN 2755. The pH for the first sample was 7.6 and for the second 2.57. The 
other two samples were collected from 2 different patients (patient 23, 26) and at the same time a 
blood sample was drawn; the pH of the sputum from the patient 23 and 26 were 7 and 7.7, 
respectively. TriN 2755 and its metabolites were detected in all four sputum samples. 
 
Discussion: 
According to this phase I trial, the maximum tolerated IV dose of TriN 2755 in dogs was determined 
to be 74.6 mg/kg. The toxicities related to the drug were in general mild in severity and include fatigue 
and gastrointestinal upset; vomitus, anorexia, nausea and diarrhea (Table 2). It is described that dogs 
receiving Dacarbazine and Temozolamide show primarily hematological, and gastrointestinal AE.13-15 
However none of the dogs in this study experienced any hematological changes related to the drug 
administration during or at the end of the study.  
The DLT is characterized by gastrointestinal AE and it did not exceed grade III. Based on the results 
of this study 3 patients in total experienced DLT; two dogs (patient 15, 26) experienced grade III 
diarrhea and one dog (patient 27) showed grade III vomitus.   
Cancer patients in a human phase I study tolerated TriN 2755 intravenously up to a total dose of 
6000mg. Only grade 1-2 fatigue, vomitus and anorexia were observed in human patients receiving 
doses of TriN 2755 ranged between 25 and 6000 mg in total. None of the humans patients experienced 
hematological toxicity.16 In contrast, dosages of TriN 2755 higher than 74.6 mg/kg (which correlates 
to 3000-4500mg in total) given to our canine patients resulted in grade 3 gastrointestinal AE. Hence, 
the tolerated dose in dogs seems to be lower than in man. Similar to Dacarbazine, TriN 2755 is an 
alkylating agent activated in the liver by CYP 450 enzymes.1 M1 and M4 are the main metabolites of 
TriN 2755. While M1 is still carrying the triazene group, M3 and M4 are the anilines obtained after 
enzymatic demethylation of the triazene group of TriN 2755 and M1 respectively.17 The inactive 
metabolite M4 is formed either after enzymatic demethylation of the triazene group of M1 via 
Cyp1A1, CYP1A2, and CYP2E1 (analogous to dacarbazine18, data not shown) or by hydrolysis of 
metabolite M3 (Figure 1).  
In humans and dogs, the extent of formation of the active metabolite M1 from TriN 2755 is higher 
than 50%. The inactive aniline metabolite M3 is formed in humans and dogs to negligible amounts 
(less than 1% and 0.1%, respectively; data not shown). Whereas the aniline metabolite M4 is further 
metabolized via N-acetylation in humans (data not shown), the absence of N-acetyltransferases in 
dogs19, 20 leads to fundamental differences in the pharmacokinetic profile of M4 between human and 
dog. By comparing the PK profile of TriN 2755 and its metabolites in dogs and humans, there are 
10fold higher concentrations of the aniline metabolite M4 of TriN 2755 detectable in dogs after a 
comparable dose of 74.6 mg/kg in dogs (absolute dose = 3453 mg) and 73.2 mg/kg (flat dose = 6000 
mg) in humans. This might be an explanation for the decreased tolerance of TriN 2755 in dogs (Figure 
2). M4 is the suspected metabolite being responsible for AE. Further in vitro studies are necessary to 
explore this hypothesis.                                                                                                                                                                                                                                                                                                                                                                                                       
Six dogs of this study receiving a dose of TriN 2755 equal or more than 62.2mg/kg vomited a 
red/orange fluid. Four sputum-samples from three of these six dogs were further evaluated; TriN 2755 
and its main metabolites were detected in all four samples and the pH for 3/4 sputum-samples ranged 
between 7.0-7.7. These results might suggest that the colored sputum is hepatic bile and TriN 2755 
and its metabolites enter the hepatobiliary circulation, considering that the normal hepatic bile of the 
dogs has a color golden yellow to orange and the pH ranges between 7.0- 7.8.21  Further investigation 
is needed to verify this hypothesis.  
This study was a dose-escalating phase I clinical trial; therefore, the response was only a secondary 
goal. Although most of the patients were treated with TriN 2755 at a dose lower than the MTD, which 
is one of the limitations of a phase I clinical trial using the “3+3” design 4, and suffered from tumors 
that are not easy to treat (e.g. disseminated histiocytic sarcoma, gastric adenocarcinoma, subcutaneous 
malignant melanoma), the responses that were registered in this study are promising.   
Twelve dogs from our study were BMDs having DHS. DHS, previously known as malignant 
histiocytosis, is a malignancy of histiocytic cell origin.22-24 DHS arises from the dendritic antigen-
presenting cells.24-26 Bernese Mountain Dogs, Flat-coated Retrievers, Labrador Retrievers and 
Rottweilers are breeds that are predisposed to HS, with the BMD showing a heritable predisposition to 
DHS.24, 26-32 DHS is a rapidly progressing multisystemic disease with a poor prognosis.23 Therefore, 
the recommended treatment is systemic chemotherapy.22 In one study Lomustine (CCNU) was given 
in 59 dogs with HS. The response rate was 46% and the median survival time (MST) for the dogs that 
responded was 172 days. The same study showed that dogs with splenic involvement had a worse 
prognosis with a MTS of 58 days.28 The course of the disease for the BMDs is referred to be even 
worse than other breeds according to two studies, giving a MST of between 30 and 49 days.29, 30 
Remarkably, one BMD with DHS showed partial remission for 450 days, one BMD had disease 
stabilization for 139 days, and a Golden Retriever for 117 days, indicating that TriN 2755 might have 
antitumor activity against malignant tumors of histiocytic origin.  
In summary, this study demonstrated a safe and tolerable dose of TriN 2755 for IV use. The AE were 
mild in severity and limited in fatigue and gastrointestinal upset. The response rates of this phase I 
clinical trial showed promising advantages of the use of this triazene, but a phase II clinical trial is 
needed to determine the efficacy of this drug. 
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Figure 1. Representative diagram of the pharmacokinetic profile of TriN 2755 and its main 
metabolites M1, M3 and M4 after a dosage of 89.6 mg/kg TriN 2755. Dots represent measured values, 
the continuous lines the calculated fits. 
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Figure 2.  The fitted concentration vs. time plots and the calculated AUCs (area under the curve) of 
the metabolite M4 formed in human and dog. 
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